Anaplastic Lymphoma Kinase (ALK) Inhibitors: Worldwide Market Analysis & Forecast 2019-2023 with F. Hoffmann-La Roche, Novartis, Pfizer, and Takeda Pharmaceutical Co Dominating – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023”
report has been added to ResearchAndMarkets.com’s
offering.

The anaplastic lymphoma kinase (ALK) inhibitors market will register a
CAGR of about 21% by 2023.

The high prevalence of lung cancer is one of the key factors
expected to trigger market growth

The increasing need for treatments coupled with the advances in
therapeutics such as targeted therapy is encouraging more and more
patients to undergo treatments using ALK inhibitor therapeutics. As a
result, owing to the strong incidence rates of the disease and the
increasing drug approvals, global ALK inhibitors market will register
considerable growth during the forecast period.

Presence of patient assistance programs

Patient assistance programs and reimbursement programs are expected to
help with the high-cost regimen of ALK inhibitors to a large extent,
which would encourage more patients to avail the treatment, thereby
driving the market growth.

Adverse effects associated with therapeutics

Despite being highly efficacious, ALK inhibitors used for treatment
NSCLC are associated with a spectrum of side effects. These side effects
hinder patient adherence to the treatment, which poses a challenge to
market growth.

Competitive Landscape

The market appears to be concentrated. ALK inhibitors have demonstrated
efficacy in the oncology indications such as NSCLC, which has been
encouraging vendors to extend their application to various other
oncology indications through additional clinical trials.

This market research report will help clients identify new growth
opportunities and design unique growth strategies by providing a
comprehensive analysis of the market’s competitive landscape and
offering information on the products offered by companies.

Key Players

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY TYPE

• Comparison by type
• Second-generation ALK inhibitors – Market size and forecast 2018-2023
• First-generation ALK inhibitors – Market size and forecast 2018-2023
• Third-generation ALK inhibitors – Market size and forecast 2018-2023
• Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• RoW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/qsnck0

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Enzymes,
Hematology